Background & Aims
Trigeminal neuralgia is a chronic orofacial neuropathic pain condition that can adversely affect quality of life. This condition primarily affects middle-aged and older females. The initial course of care involves drug management, and in some patients, lifelong medical care may be necessary. This study aims to explore factors correlated with the failure of medical treatment in patients with classical trigeminal neuralgia (TN) who received care at the tertiary Orofacial Pain Centre between 2002 and 2022.
Methods
We conducted an analysis of 33 phenotypic and treatment outcomes data from 379 classical trigeminal neuralgia patients using binary logistic regression. In the initial model, we selected variables with a p-value ? 0.25, incorporating factors previously studied for their association with treatment outcomes. These selected variables were then included in the final model. The final model employed multiple logistic regression statistics to assess the relationships between various factors and variables. Factors and variables with a p-value ? 0.05 were considered significantly correlated with the failure of medication treatment.
Results
The majority of patients were female (77.3%), with an average age of 58.67 ± 13.08 years. The right side of the face was predominantly affected (62.3%), especially in the region supplied by the mandibular branch of the trigeminal nerve (34.6%). In the final model analysis, factors associated with trigeminal neuralgia medical treatment failure included the presence of symptoms of autonomic nervous system (OR:3.53; p-value = 0.04), an onset of pain exceeding 12 months (OR:2.97; p-value = 0.006), no history of spontaneous remission (OR:5.17; p-value = 0.007), and receiving non-sodium channel blockers medications (OR:3.97; p-value = 0.004).
Conclusions
In classical trigeminal neuralgia patients; longer duration of pain, autonomic nervous system symptoms and the absence of natural remission period increased risk of medical treatment failure. Thorough history taking and examination, is useful for the success of trigeminal neuralgia management.
References
1. Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia–a
prospective systematic study of clinical characteristics in 158 patients.
Headache. 2014;54(10):1574–1582.
2. Olesen J. Headache Classification Committee of the International Headache
Society (IHS) The International Classification of Headache Disorders, 3rd
edition. Cephalalgia. 2018 Jan;38(1):1–211.
3. Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200
outpatients with classical trigeminal neuralgia treated with carbamazepine or
oxcarbazepine in a tertiary centre for neuropathic pain. J Headache Pain. 2014
Jun;15(1):34.
4. Lim K-S, Kwan P, Tan C. Association of HLA-B*1502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review.
Neurol Asia. 2008 Jun 1;13:15–21.
5. Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH, et al. Association
between HLA-B*1502 allele and antiepileptic drug-induced cutaneous
reactions in Han Chinese. Epilepsia. 2007 May;48(5):1015–1018.
6. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin S-Y, Chen W-H,
et al. Association between HLA-B*1502 and carbamazepine-induced severe
cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010
May;51(5):926–930.
7. Jainkittivong A, Aneksuk V, Langlais RP. Trigeminal neuralgia: a retrospective
study of 188 Thai cases. J. Gerontol. 2012 Jun;29(2):611-617.
8. Di Stefano G, De Stefano G, Leone C, Di Lionardo A, Di Pietro G, Sgro E, et al.
Real-world effectiveness and tolerability of carbamazepine and oxcarbazepine
in 354 patients with trigeminal neuralgia. Eur J Pain. 2021 May;25(5):1064–
1071.
9. Simms HN, Honey CR. The importance of autonomic symptoms in trigeminal
neuralgia. Clinical article. J Neurosurg. 2011 Aug;115(2):210–216.
10. Sarideechaigul W, Kitkhuandee A, Siritapetawee M, Butda P, Jorns TP. Profiling
of patients presenting with trigeminal neuralgia and outcomes of medical
management in a tertiary care center. J Med Assoc Thail. 2019;102(4):57–62.
11. Hardy DG, Rhoton ALJ. Microsurgical relationships of the superior cerebellar
artery and the trigeminal nerve. J Neurosurg. 1978 Nov;49(5):669–678.
12. Malicki M, Szmyd BM, Bobeff EJ, Karuga FF, Piotrowski MM, et al. The Superior
Cerebellar Artery: Variability and Clinical Significance. Biomedicines. 2023
Jul;11(7).
13. Kaeley N, Kabi A, Bhatia R, Mohanty A. Carbamazepine-induced hyponatremia
– A wakeup call. J Family Med Prim Care. 2019 Jan 1;8(5):1786-1788.
14. Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced
hyponatremia, a cross-sectional study. Epilepsy Res. 1988;2(4):269–271.
15. Berghuis B, van der Palen J, de Haan G-J, Lindhout D, Koeleman BPC, Sander
JW. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with
epilepsy. Epilepsia. 2017 Jul;58(7):1227–1233.
16. Daughton J. Careful monitoring for agranulocytosis during carbamazepine
treatment. Prim Care Companion J Clin Psychiatry. 2006 Oct 16;8(5):310-311.
17. Hughes JR, DeTolve-Donoghue M. Chronic leukopenia associated with
carbamazepine and other antiepileptic drugs. J Epilepsy. 1995;8(4):282-288.
18. SNI SO, NA M, TG K. Evaluation of Carbamazepine Pharmacotherapy In Patients
With Trigeminal Neuralgia. Ann Dent. 2016;23(2):19–26.
19. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol
Scand. 2008 Nov;118(5):281–290.
20. Ota M, Funakoshi T, Aki T, Unuma K, Uemura K. Oxcarbazepine induces mitotic
catastrophe and apoptosis in NRK-52E proximal tubular cells. Toxicol Lett.
2021;350:240–248.
21. Melek LN, Devine M, Renton T. The psychosocial impact of orofacial pain in
trigeminal neuralgia patients: a systematic review. Int J Oral Maxillofac Surg.
2018;47(7):869–878.
22. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS
guidelines on trigeminal neuralgia management. Eur J Neurol. 2008
Oct;15(10):1013–1028.
23. Gambeta E, Chichorro JG, Zamponi GW. Trigeminal neuralgia: An overview from
pathophysiology to pharmacological treatments. Mol Pain.
2020;16:1744806920901890.
24. Anukoolwittaya P, Thanprasertsuk S, Phanthumchinda K. A transformation of
trigeminal neuralgia into SUNCT/SUNA: A case report and literature review.
Headache Med. 2023 Mar 31;14:59–64.
25. Love S, Coakham HB. Trigeminal neuralgia: Pathology and pathogenesis. Brain.
2001 Dec 1;124(12):2347–2360.
Presenting Author
Teekayu Jorns
Poster Authors
Teekayu Jorns
DDS., PhD.
Khon Kaen University, Thailand
Lead Author
Nathida Boonpracong
Faculty of Dentistry, Khon Kaen University, Thailand
Lead Author
Worapong Issariyawinyu
Faculty of Dentistry, Khon Kaen University, Thailand
Lead Author
Sirin Tongsiri
Faculty of Dentistry, Khon Kaen University, Thailand
Lead Author
Rajda Chaichit
Faculty of Dentistry, Khon Kaen University, Thailand
Lead Author
Topics
- Specific Pain Conditions/Pain in Specific Populations: Orofacial Pain